|
Chief Research Officer Dr. Stephen Rose weighs in on ACT’s clinical trials that use retinal cells derived from human stem cells to treat macular degeneration. The MIT Technology Review article appears online after ACT announced two patients were treated Tuesday in California. Read the full article >
|
